Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Esophageal Cancer
Interventions: filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 97
States / cities: Burbank, California • Hayward, California • Mission Hills, California + 72 more

Conditions: Gaucher's Disease
Interventions: human glucocerebrosidase cDNA; Genetic
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: Interleukin-2; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
Interventions: Vaccine (autologous dendritic cells), Decitabine and Hiltonol; Biological · Drug
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Louisville, Kentucky

Conditions: Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
Interventions: Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions: Administration of autologous adipose derived SVF; Procedure
Lead sponsor: Elliot Lander; Industry
Eligibility: 16 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rancho Mirage, California

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Involved-Field Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Quality-of-Life Assessment; Procedure · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 58
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Encinitas, California + 45 more

Conditions: Health Status Unknown
Interventions: Autologous Fat Graft, Reconstructive Surgery; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cytokine Release Syndrome
Interventions: Itacitinib, Immune effector cell therapy, Placebo, Yescarta; Drug · Biological
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Miami, Florida • Tampa, Florida • Boston, Massachusetts + 6 more

Conditions: Rheumatoid Arthritis
Interventions: Sofusa DoseConnect, Enbrel; Device · Drug
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Congestive Heart Failure, Heart Failure, Diastolic
Interventions: Allogeneic Derived Cells, Placebo/Control Arm; Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Lung Cancer
Interventions: Erlotinib, SBRT; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Dallas, Texas

Conditions: Infertility
Interventions: Trophectoderm biopsy, Cryopreservation, Embryo Transfer; Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania

Conditions: Brain and Central Nervous System Tumors
Interventions: imatinib mesylate, local irradiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 10
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more

Conditions: CMV, EBV, Adenovirus Infections
Interventions: Cytotoxic T lymphocytes (CTLs).; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 4 Weeks and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Houston, Texas

Conditions: Multiple Myeloma
Interventions: Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances; Diagnostic Test · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Frailty
Interventions: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Placebo, Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs); Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: 60 Years to 95 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Peripheral Arterial Disease
Interventions: Supervised Treadmill Exercise Therapy, Health education sessions (Control), granulocyte macrophage colony stimulating factor (GM-CSF); Behavioral · Other · Drug
Lead sponsor: Northwestern University; Other
Eligibility: Not listed
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: Infusion of NEXI-001 T Cells; Biological
Lead sponsor: NexImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Duarte, California • Orlando, Florida • Detroit, Michigan + 2 more

Conditions: CD 19+ Acute Leukemia
Interventions: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC); Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Year to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2033
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anemia, Sickle Cell
Interventions: Types of Telemedicine Delivery Models; Other
Lead sponsor: Indiana University; Other
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Fanconi Anemia
Interventions: Bone Marrow Aspiration, Filgrastim, Genetically Engineered Hematopoietic Stem Progenitor Cells, Laboratory Biomarker Analysis, Leukapheresis, Methylprednisolone, Plerixafor, Prednisone; Procedure · Biological · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 4 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Recent Myocardial Infarction, Ventricular Dysfunction
Interventions: Autologous stem cell infusion; Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Medication Adherence
Interventions: Cell Phone Support; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 15 Years to 21 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells

Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Autologous Fat Grafting Techniques in Patients Undergoing Reconstructive Surgery

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The PrISICE Clinical Trial (Pre-Implantation Screening and Investigation on the Cryopreservation of Embryos)

Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

Cytotoxic T Cells to Prevent Virus Infections

Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery

Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)

Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

Telemedicine for Children With Sickle Cell Disease

Gene Therapy for Fanconi Anemia

CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction

Cell Phone Support to Promote Medication Adherence Among Adolescents and Young Adults With Chronic Illness